Business
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps (\"NETs\") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platformFRAMINGHAM, MA / ACCESSWIRE / November 16, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of Jonathan Spicer, MD, PhD to its Scientific Advisory Board (\"SAB\").Dr. Spicer is recognized as a leader in understanding how neutrophils impact cancer progression, in particular, the role of NETs in cancer biology, and has developed one of the most active research programs in the area of neoadjuvant immunotherapy for operable lung cancer.\"Dr. Spicer's research of NETs and their impact on cancer adds valuable insight and leadership regarding our recently in-licensed DNase-oncology platform and will provide key expertise as we look to advance the program towards our planned Phase 1 study. We are very pleased to welcome Jonathan to our SAB and we look forward to leveraging his extensive experience and understanding of the role NETs play in the progression of cancer,\" commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.Dr. Spicer is a seasoned surgeon scientist that currently serves as an Associate Professor of Surgery at McGill University and Medical Director of the McGill University Health Center (MUHC) Thoracic Oncology Network. Dr. Spicer also leads a broad research program covering basic, translational, and clinical research topics. Additionally, Dr. Spicer chairs the McGill Regional Thoracic Oncology Tumor Board and is Co-Director of the MUHC Thoracic Oncology Clinical Trials Unit. He is the Program Director for the McGill Advanced Thoracic and Upper GI Surgical Oncology Fellowship. Dr. Spicer is the Research Chair for the Canadian Association of Thoracic Surgeons, Director of the Canadian Cancer Trials Mesothelioma Working Group and sits on numerous steering committees for Phase 2 and 3 international trials investigating the use of novel therapies prior to lung cancer resections. He trained in general surgery at McGill University where earned his MD and subsequently in cardiothoracic surgery at the U...